邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位

金媛媛,  庄俊玲

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(3): 219-223
金媛媛, 庄俊玲. 新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J]. 协和医学杂志, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
引用本文: 金媛媛, 庄俊玲. 新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J]. 协和医学杂志, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
shu
Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
Citation: Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
shu

新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位

doi: 10.3969/j.issn.1674-9081.2018.03.006

  • 中国医学科学院 北京协和医学院 北京协和医院血液内科, 北京 100730

基金项目: 

中国医学科学院创新工程项目 CAMS-2016-I2M-3-025

详细信息
    通讯作者:

    庄俊玲 电话:010-69155027, E-mail:zhuangjunling@pumch.cn

  • 中图分类号: R457.7;R733.3

Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 多发性骨髓瘤(multiple myeloma, MM)患者的总生存期(overall survival, OS)在过去20年间从3年延长至8~10年, 这得益于蛋白酶体抑制剂和免疫调节药物等的广泛应用。即使在新药时代, 自体造血干细胞移植(autologous stem cell transplantation, ASCT)仍可显著提高移植后反应率, 增加微小残留病变阴性率, 延长无进展生存期。ASCT对OS的影响在不同研究中结果并不一致, 这主要与进展后采用不同治疗方案有关。随着更多新药的出现, ASCT后复发患者会有更多选择。故新药时代, ASCT仍是MM患者诱导治疗后的一线巩固方案。
    Abstract: The overall survival(OS) in patients with multiple myeloma (MM) has been prolonged from 3 years to 8-10 years during the past 20 years, which benefits from the broad use of novel agents including proteasome inhibitors and immune modulatory drugs. Even in the era of novel medicines, high-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard treatment for transplant candidates of newly diagnosed MM. ASCT significantly further improves the post-transplant response rate and the proportion of negative minimal residual disease, as well as leading to better progression-free survival. Nevertheless, the effect of ASCT on OS was not consistent among different clinical trials, which was probably related to different strategies after relapse. As other novel methods including monoclonal antibodies and immune therapies are being developed, more alternatives will be considered. Therefore, ASCT is still the front-line consolidation regimen for transplant candidates with MM.
    • HTML全文
    • 参考文献(27)
  • [1] Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22:5419-5427. doi:  10.1158/1078-0432.CCR-16-0625
    [2] McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651
    [3] Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome[J]. N Engl J Med, 1996, 335:91-97. doi:  10.1056/NEJM199607113350204
    [4] Child JA, Morgan GJ, Davies FE, et al. Medical research council adult leukaemia working party. High-dose chemo-therapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi:  10.1056/NEJMoa022340
    [5] Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J]. Blood, 2011, 118:529-534. http://europepmc.org/abstract/MED/21482708
    [6] Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2003, 349:2495-2502. doi:  10.1056/NEJMoa032290
    [7] Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA[J]. Blood, 2005, 106:3755-3759. http://www.tandfonline.com/servlet/linkout?suffix=CIT0008&dbid=16&doi=10.1517%2F14656566.7.2.195&key=10.1182%2Fblood-2005-03-1301
    [8] Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:a phase Ⅱ study by the Intergroupe Francophone du Myélome[J]. J Clin Oncol, 2014, 32:2712-2717. doi:  10.1200/JCO.2013.54.8164
    [9] Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplan, 2007, 13:183-196. doi:  10.1016/j.bbmt.2006.09.010
    [10] Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma:a meta-analysis of phase Ⅲ randomized, controlled trials[J]. J Clin Oncol, 2013, 31:3279-3287. doi:  10.1200/JCO.2012.48.4626
    [11] Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28:4621-4629. doi:  10.1200/JCO.2009.27.9158
    [12] Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30:2946-2955. doi:  10.1200/JCO.2011.39.6820
    [13] Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120:1589-1596. http://www.tandfonline.com/servlet/linkout?suffix=CIT0047&dbid=16&doi=10.1080%2F17474086.2018.1437345&key=10.1182%2Fblood-2012-02-408922
    [14] Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study[J]. Lancet, 2010, 376:2075-2085. doi:  10.1016/S0140-6736(10)61424-9
    [15] Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma[J]. N Engl J Med, 2014, 371:895-905. doi:  10.1056/NEJMoa1402888
    [16] Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J]. Blood, 2010, 116:679-686. http://europepmc.org/articles/PMC3324254/
    [17] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi:  10.1056/NEJMoa1611750
    [18] Attal M, Harousseau JL, Leyvraz S, et al. Maintenance the-rapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108:3289-3294. http://europepmc.org/abstract/MED/16873668
    [19] Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27:1788-1793. doi:  10.1200/JCO.2008.18.8573
    [20] Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354:1021-1030. doi:  10.1056/NEJMoa053583
    [21] Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalido-mide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J]. Blood, 2008, 112:3115-3121. http://www.ncbi.nlm.nih.gov/pubmed/18492953
    [22] Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma[J]. Blood, 2010, 115:1113-1120. doi:  10.1182/blood-2009-05-222539
    [23] Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J]. Blood, 2012, 119:7-15. doi:  10.1182/blood-2011-06-357038
    [24] Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1782-1791. doi:  10.1056/NEJMoa1114138
    [25] McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1770-1781. doi:  10.1056/NEJMoa1114083
    [26] Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma[J]. Biol Blood Marrow Transplant, 2013, 19:760-766. doi:  10.1016/j.bbmt.2013.01.004
    [27] Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J]. Cancer, 2012, 118:1585-1592. doi:  10.1002/cncr.26422
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  335
  • HTML全文浏览量:  53
  • PDF下载量:  255
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-13
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！